Tests a digital lifestyle tool with AI chat for type 2 diabetes
Tests a digital lifestyle tool with AI chat in adults with type 2 diabetes.
Plain-language title generated from the registry record
Registry title: Effect of the Digital Livsstilsverktyget in Conjunction With a Large Language Model on Glycemic Control in Patients With Type 2 Diabetes.
Key facts
- Where
- Malmö, SwedenSee the site
Where in Sweden
- Clinical Research CenterMalmö, SwedenTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Region Skane
- Trial code
- NCT07079189
- Record updated
- 14 August 2025
- Original description
The overall aim of the study is to observe the change of long-term metabolic control in patients with type 2 diabetes who have access to a digital intervention tool as compared with randomized controls during one year. The tool is based on self-affirmation theory and has large emphasis on self-reflection to enable sustainable lifestyle changes. Users get access to expert-written information about relevant health topics and interact with an LLM to promote reflection on the information.Read full original descriptionShow less
Personalized Study of Type 2 Diabetes With the Lifestyle Tool
The overall aim of the study is to observe the change of long-term metabolic control in patients with type 2 diabetes who have access to a digital intervention tool as compared with randomized controls during one year. The tool is based on self-affirmation theory and has large emphasis on self-reflection to enable sustainable lifestyle changes. Users get access to expert-written information about relevant health topics and interact with an LLM to promote reflection on the information.
Inclusion: Patients with type 2 diabetes; Diagnosis of diabetes mellitus was based on prior documentation or treatment with anti-hyperglycemic medication; age at or above 35 years; access to Internet; informed consent.
Exclusion: Treatment with insulin; Change of anti-diabetic treatment with three months prior to inclusion; Condition or treatment that in the judgement of the Investigator precludes participation; Participation in other study that may affect the outcomes; Inability to read and write in Swedish; Work in competing areas.